[go: up one dir, main page]

AR001405A1 - Formulación oral de 2-metil-tieno-beno-diacepina. - Google Patents

Formulación oral de 2-metil-tieno-beno-diacepina.

Info

Publication number
AR001405A1
AR001405A1 AR33587496A AR33587496A AR001405A1 AR 001405 A1 AR001405 A1 AR 001405A1 AR 33587496 A AR33587496 A AR 33587496A AR 33587496 A AR33587496 A AR 33587496A AR 001405 A1 AR001405 A1 AR 001405A1
Authority
AR
Argentina
Prior art keywords
oral formulation
ethyl acrylate
beno
diazepine
thieno
Prior art date
Application number
AR33587496A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23624847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR001405(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR001405A1 publication Critical patent/AR001405A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Una formulación oral sólida que comprende olanzapina como ingrediente activo, mezclada íntimamente con un agente de carga; aglutinante, disgregante,un aglutinante seco para proporcionar friabilidad adecuada, y un lubricante; en la que dicha formulación oral sólida está recubierta con un polímeroseleccionado entre el grupo formado por hidroxipropil hipromelosa, hidroxietil celulosa, metilhidroxietilcelulosa, carboxihipromelosa de sodio, hidroxipropilcelulosa, polivinilpirrolidona, copolímero del éster dimetilaminetílico metacrilato-éster dimetilaminoetílico metilacrilato, copolímero deetilacrilato-metilmetacrilato, hipromelosa y etilcelulosa.
AR33587496A 1995-03-24 1996-03-22 Formulación oral de 2-metil-tieno-beno-diacepina. AR001405A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41046595A 1995-03-24 1995-03-24

Publications (1)

Publication Number Publication Date
AR001405A1 true AR001405A1 (es) 1997-10-22

Family

ID=23624847

Family Applications (2)

Application Number Title Priority Date Filing Date
AR33587496A AR001405A1 (es) 1995-03-24 1996-03-22 Formulación oral de 2-metil-tieno-beno-diacepina.
ARP960101877A AR002720A1 (es) 1995-03-24 1996-03-22 Proceso para preparar una composición oral sólida de olanzapina con subrecubrimiento de polímero y recubrimiento coloreado

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP960101877A AR002720A1 (es) 1995-03-24 1996-03-22 Proceso para preparar una composición oral sólida de olanzapina con subrecubrimiento de polímero y recubrimiento coloreado

Country Status (46)

Country Link
US (4) US5919485A (es)
EP (2) EP1093815B1 (es)
JP (1) JPH11502848A (es)
KR (1) KR100408172B1 (es)
CN (1) CN1178662C (es)
AP (1) AP679A (es)
AR (2) AR001405A1 (es)
AT (3) AT405606B (es)
AU (1) AU696601B2 (es)
BG (1) BG62594B1 (es)
BR (1) BR9607791A (es)
CA (1) CA2216372C (es)
CH (1) CH691217A5 (es)
CO (1) CO4700474A1 (es)
CR (1) CR5278A (es)
CZ (1) CZ296007B6 (es)
DE (3) DE69615887T2 (es)
DK (3) DK1093815T3 (es)
EA (1) EA000938B1 (es)
EE (1) EE03551B1 (es)
EG (1) EG24077A (es)
ES (2) ES2232379T3 (es)
FI (1) FI973749A7 (es)
GB (1) GB2313783B (es)
HU (1) HU225269B1 (es)
IL (1) IL117611A (es)
IS (1) IS1903B (es)
LT (1) LT4350B (es)
LU (1) LU90115B1 (es)
LV (1) LV11983B (es)
MY (1) MY113440A (es)
NO (1) NO320388B1 (es)
NZ (1) NZ306111A (es)
OA (1) OA10511A (es)
PE (1) PE44997A1 (es)
PL (1) PL188316B1 (es)
PT (2) PT1093815E (es)
RO (1) RO118370B1 (es)
SE (1) SE9703206D0 (es)
SI (3) SI1093815T1 (es)
SK (1) SK283745B6 (es)
TR (1) TR199701018T1 (es)
TW (1) TW426526B (es)
UA (1) UA44766C2 (es)
WO (1) WO1996029995A1 (es)
ZA (1) ZA962338B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
CN1230883A (zh) * 1996-09-24 1999-10-06 伊莱利利公司 包衣颗粒制剂
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
WO2001047933A1 (en) * 1999-12-28 2001-07-05 Cipla Limited New polymorphic forms of olanzapine
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
US20030072729A1 (en) * 2001-05-15 2003-04-17 Christopher Szymczak Simethicone as weight gain enhancer
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
CA2477088A1 (en) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU2002255196A1 (en) * 2002-04-18 2003-10-27 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
SI1513846T1 (sl) 2002-05-31 2011-11-30 Sandoz Ag Postopek za pripravo olanzapina form I
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US7029112B2 (en) 2002-08-05 2006-04-18 Mars, Incorporated Ink-jet printing on surface modified edibles and products made
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
CA2785138A1 (en) * 2003-10-07 2005-04-21 Andrx Pharmaceuticals Llc Rapidly disintegrating formulation
AU2004291043A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US7785635B1 (en) * 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
EP1838716B1 (en) 2005-01-05 2011-06-01 Eli Lilly And Company Olanzapine pamoate dihydrate
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
PL385455A1 (pl) * 2005-04-22 2008-11-24 Teva Pharmaceuticals Usa,Inc. Doustna rozpadająca się farmaceutyczna tabletka preparatów olanzapiny
WO2006130188A1 (en) * 2005-05-31 2006-12-07 The Iams Company Feline probiotic bifidobacteria
DK1880001T3 (da) * 2005-05-31 2011-09-12 Iams Company Feline probiotiske lactobacilli
US20070014847A1 (en) * 2005-07-05 2007-01-18 Ahmed Salah U Coated capsules and methods of making and using the same
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
WO2008004033A1 (en) * 2006-07-05 2008-01-10 Bilim Ilac Sanayii Ve Ticaret A.S. A stable olanzapine formulation with antioxidants
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
CN101711158A (zh) 2007-02-01 2010-05-19 爱默思公司 使用葡萄糖抗代谢物、鳄梨或鳄梨提取物减轻哺乳动物炎症和应激反应的方法
JP4656672B2 (ja) * 2008-01-31 2011-03-23 杏林製薬株式会社 イミダフェナシンを有効成分とする口腔内速崩錠の製造方法
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US20110048048A1 (en) * 2009-03-25 2011-03-03 Thomas Gielda Personal Cooling System
US8505322B2 (en) * 2009-03-25 2013-08-13 Pax Scientific, Inc. Battery cooling
BRPI1012630A2 (pt) * 2009-03-25 2017-09-12 Caitin Inc sistema de resfriamento supersônico
US20110051549A1 (en) * 2009-07-25 2011-03-03 Kristian Debus Nucleation Ring for a Central Insert
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8365540B2 (en) * 2009-09-04 2013-02-05 Pax Scientific, Inc. System and method for heat transfer
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9517212B1 (en) * 2012-11-15 2016-12-13 Chandra Zaveri Medicated adhesive pad arrangement
CN103919782B (zh) * 2013-01-15 2016-12-28 天津药物研究院有限公司 一种含有奥氮平的药物组合物及其制备方法
EP3043778B1 (en) * 2013-09-13 2017-09-06 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
CN107007559B (zh) * 2017-04-21 2020-05-15 浙江京新药业股份有限公司 一种稳定的口服药物组合物及其制备方法
EP4378463A3 (en) * 2017-06-02 2024-10-23 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
CN113143878A (zh) * 2021-03-19 2021-07-23 杭州新诺华医药有限公司 奥氮平组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172831A (en) * 1974-11-26 1979-10-30 Lilly Industries Limited Thieno-benzodiazepines
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
ZA922777B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical formulation containing dirithromycin
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
DK0582368T3 (da) * 1992-05-29 2001-02-05 Lilly Co Eli Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Also Published As

Publication number Publication date
SI1093815T1 (en) 2005-06-30
IS1903B (is) 2003-11-20
GB2313783B (en) 1998-11-18
EG24077A (en) 2008-05-11
JPH11502848A (ja) 1999-03-09
DK1093815T3 (da) 2005-04-25
DK0733367T3 (da) 2001-11-26
FI973749A0 (fi) 1997-09-22
AR002720A1 (es) 1998-04-29
AU696601B2 (en) 1998-09-17
CA2216372A1 (en) 1996-10-03
CO4700474A1 (es) 1998-12-29
US5919485A (en) 1999-07-06
KR100408172B1 (ko) 2004-02-18
US6780433B2 (en) 2004-08-24
SE9703206L (sv) 1997-09-05
US6190698B1 (en) 2001-02-20
LT4350B (lt) 1998-05-25
ATA902296A (de) 1999-02-15
EE9700328A (et) 1998-06-15
LV11983A (lv) 1998-03-20
AU5428096A (en) 1996-10-16
FI973749L (fi) 1997-09-22
TR199701018T1 (xx) 1998-01-21
DE69634053D1 (de) 2005-01-20
EP0733367B1 (en) 2001-10-17
AP679A (en) 1998-09-28
HUP9800410A2 (hu) 1998-07-28
DE19681287T1 (de) 1998-03-19
LU90115B1 (fr) 1997-09-10
UA44766C2 (uk) 2002-03-15
HU225269B1 (en) 2006-08-28
BG101901A (bg) 1998-10-30
EP1093815A1 (en) 2001-04-25
EA199700260A1 (ru) 1998-02-26
CZ300197A3 (en) 1997-12-17
CZ296007B6 (cs) 2005-12-14
EP1093815B1 (en) 2004-12-15
RO118370B1 (ro) 2003-05-30
US20010018071A1 (en) 2001-08-30
ATE284695T1 (de) 2005-01-15
EP0733367A1 (en) 1996-09-25
MX9707186A (es) 1997-11-29
LT97149A (lt) 1998-01-26
DE69615887D1 (de) 2001-11-22
HUP9800410A3 (en) 2000-01-28
PE44997A1 (es) 1997-10-23
NO974363L (no) 1997-11-17
CA2216372C (en) 2007-11-20
OA10511A (en) 2002-04-24
NZ306111A (en) 1999-02-25
US20050085462A1 (en) 2005-04-21
AT405606B (de) 1999-10-25
SI9620041A (sl) 1998-06-30
GB2313783A (en) 1997-12-10
IL117611A (en) 2002-05-23
NO320388B1 (no) 2005-11-28
SI0733367T1 (en) 2002-06-30
CR5278A (es) 1996-07-04
US7229643B2 (en) 2007-06-12
IL117611A0 (en) 1996-07-23
DK109097A (da) 1997-11-12
ATE206924T1 (de) 2001-11-15
BR9607791A (pt) 1998-07-07
SE9703206D0 (sv) 1997-09-05
DE69634053T2 (de) 2005-12-22
IS4565A (is) 1997-09-22
WO1996029995A1 (en) 1996-10-03
CN1178662C (zh) 2004-12-08
MY113440A (en) 2002-02-28
FI973749A7 (fi) 1997-09-22
BG62594B1 (bg) 2000-03-31
ES2232379T3 (es) 2005-06-01
AP9701064A0 (en) 1997-10-31
LV11983B (en) 1998-07-20
SK283745B6 (sk) 2003-12-02
EE03551B1 (et) 2001-12-17
CH691217A5 (de) 2001-05-31
PL188316B1 (pl) 2005-01-31
DK173323B1 (da) 2000-07-24
PT733367E (pt) 2002-03-28
DE69615887T2 (de) 2002-04-11
PT1093815E (pt) 2005-03-31
CN1179102A (zh) 1998-04-15
PL322579A1 (en) 1998-02-02
SK128297A3 (en) 1998-03-04
GB9719817D0 (en) 1997-11-19
EA000938B1 (ru) 2000-06-26
ZA962338B (en) 1997-09-22
NO974363D0 (no) 1997-09-22
ES2164837T3 (es) 2002-03-01
KR19980703189A (ko) 1998-10-15
TW426526B (en) 2001-03-21

Similar Documents

Publication Publication Date Title
AR001405A1 (es) Formulación oral de 2-metil-tieno-beno-diacepina.
CL2004001182A1 (es) Composicion farmaceutica que comprende a una microparticula de liberacion sostenida la que contiene a un derivado de 1,2 benzazol; procedimiento de preparacion de la microparticula; util como broncodilatador, antipsicoticos y en otros problemas del s
AR049055A2 (es) Una tableta rapidamente desintegrable para la administracion por via oral
US6509037B2 (en) Sustained release pharmaceutical matrix tablet of pharmaceutically acceptable salts of diclofenac and process for preparation thereof
ES2107235T3 (es) Tableta de liberacion prolongada, revestida con pelicula, de astemizol y pseudoefedrina.
ES2159591T3 (es) Composicion de liberacion controlada.
AR036972A1 (es) Tableta bioadhesiva de hidratacion progresiva y liberacion sostenida y su uso en la fabricacion de un agente farmaceutico
IS6209A (is) Ný blanda
KR950007841A (ko) 트라마돌 염을 함유하는 서방성 약물 제제
ES2094781T3 (es) Composicion farmaceutica de microparticulas con liberacion controlada y su proceso de preparacion.
EA200200595A1 (ru) Лекарственная форма с высвобождением лекарства под действием гидрогеля
EE05022B1 (et) Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat
AR020610A1 (es) Utilizacion de un copolimero de acido metacrilico de tipo c segun la farmacopea us national formulary usp/nf, como agente de desagregacion y el procedimiento de fabricaion de un comprimido con dicho copolimero
PE20000544A1 (es) Forma de dosificacion de nefazodona
EA200001201A3 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
FR2752732B1 (fr) Forme galenique a liberation prolongee de milnacipran
ES2111547T3 (es) Comprimido de liberacion prolongada.
DE60023107D1 (de) Zubereitungen mit verbesserter kontrollierter freisetzung
AR003928A1 (es) Comprimido del liberacion controlada
KR870000069A (ko) 안정한 고체 제형의 제조 방법
PT1318792E (pt) Composicao de libertacao prolongada que contem claritromicina
ES2196620T3 (es) Formulacion de liberacion prolongada que contiene venlafaxina.
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
EE9600202A (et) Toimeaine pärsitud vabanemisega karbamasepiini ravimvorm
ECSP961693A (es) Formulacion oral de 2- metil-tieno-benzodiaceptina

Legal Events

Date Code Title Description
FC Refusal